Frontiers in Acute Pain Management: Emerging Concepts in Pain Pathways and the Role of VX-548 as a Novel NaV1.8 Inhibitor: A Narrative Review

Purpose of Review Despite ongoing research into alternative postsurgical pain treatments, opioids remain widely used analgesics regardless of associated adverse effects, including dependence and overdose, as demonstrated throughout the current opioid crisis. This is likely related to a failure in pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current pain and headache reports 2024-11, Vol.28 (11), p.1135-1143
Hauptverfasser: Kaye, Alan D., Everett, Erin S., Lehuquet, Arianna M., Mason, Joseph W., Maitski, Rebecca, Plessala, Michael J., Barrie, Sonnah, Baptiste, Carlo Jean, Mychaskiw, George, Ahmadzadeh, Shahab, Shekoohi, Sahar, Varrassi, Giustino
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1143
container_issue 11
container_start_page 1135
container_title Current pain and headache reports
container_volume 28
creator Kaye, Alan D.
Everett, Erin S.
Lehuquet, Arianna M.
Mason, Joseph W.
Maitski, Rebecca
Plessala, Michael J.
Barrie, Sonnah
Baptiste, Carlo Jean
Mychaskiw, George
Ahmadzadeh, Shahab
Shekoohi, Sahar
Varrassi, Giustino
description Purpose of Review Despite ongoing research into alternative postsurgical pain treatments, opioids remain widely used analgesics regardless of associated adverse effects, including dependence and overdose, as demonstrated throughout the current opioid crisis. This is likely related to a failure in proving the efficacy of alternative analgesics in clinical trials, despite strong evidence supporting the potential for effective analgesia through in vitro studies. While NaV1.7 and NaV1.8 channels have shown to be key components of pain perception, studies regarding pharmacological agents utilizing these channels as targets have largely failed to demonstrate the efficacy of these proposed analgesics when compared to current multimodal pain treatment regimens. Recent Findings However, the novel NaV1.8 channel inhibitor, VX-548 has surpassed previously studied NaV1.8 inhibitors in clinical trials and continues to hold promise of a novel efficacious analgesic to potentially be utilized in multimodal pain treatment on postsurgical patients. Additionally, NaV1.8 is encoded by the SCN10A, which has been shown to be minimally expressed in the brain, suggesting a lower likelihood of adverse effects in the CNS, including dependence and abuse. Summary Novel pharmacologic analgesics that are efficacious without the significant side effects associated with opioids have lacked meaningful development. However, recent clinical trials have shown promising results in the safety and efficacy of the pharmacological agent VX-548. Still, more clinical trials directly comparing the efficacy of VX-548 to standard of care post-surgical drugs, including opioids like morphine and hydromorphone are needed to demonstrate the long-term viability of the agent replacing current opioids with an unfavorable side effect profile.
doi_str_mv 10.1007/s11916-024-01295-7
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3075704821</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3075704821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-3cb7832664a45aea833a71337993bd6d185375bde0a99a9ab6b62238dfbfa0c3</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0EomXhBTggS1x6SfG_xE5vq1ULlUqpUFVxsybJZDdVYi-2s1UfgnfG7BaQOHCa0czv-2akj5C3nJ1yxvSHyHnNq4IJVTAu6rLQz8gxL6UqJDP8-b7nhVRSHpFXMd4zJpgx_CU5kqauZMnVMflxEbxLA4ZIB0eX7ZyQ3kBuP4ODNU7o0hk9nzCsB7emK-9a3KY9u6duIG0e4DFScB1NG6Rf_YjU9_TuW1EqQyFv6LXf4Uiv4Y6fGnrpNkMzJB_O6DLPQoA07LIOdwM-vCYvehgjvnmqC3J7cX67-lRcffl4uVpeFa0oq1TIttFGiqpSoEpAMFKC5lLqupZNV3XclFKXTYcM6hpqaKqmEkKarm96YK1ckJOD7Tb47zPGZKchtjiO4NDP0UqmS82UETyj7_9B7_0cXH7OSs6V0Erk6wsiDlQbfIwBe7sNwwTh0XJmf2VlD1nZnJXdZ2V1Fr17sp6bCbs_kt_hZEAegJhXbo3h7-3_2P4EnwWcvg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3114274283</pqid></control><display><type>article</type><title>Frontiers in Acute Pain Management: Emerging Concepts in Pain Pathways and the Role of VX-548 as a Novel NaV1.8 Inhibitor: A Narrative Review</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kaye, Alan D. ; Everett, Erin S. ; Lehuquet, Arianna M. ; Mason, Joseph W. ; Maitski, Rebecca ; Plessala, Michael J. ; Barrie, Sonnah ; Baptiste, Carlo Jean ; Mychaskiw, George ; Ahmadzadeh, Shahab ; Shekoohi, Sahar ; Varrassi, Giustino</creator><creatorcontrib>Kaye, Alan D. ; Everett, Erin S. ; Lehuquet, Arianna M. ; Mason, Joseph W. ; Maitski, Rebecca ; Plessala, Michael J. ; Barrie, Sonnah ; Baptiste, Carlo Jean ; Mychaskiw, George ; Ahmadzadeh, Shahab ; Shekoohi, Sahar ; Varrassi, Giustino</creatorcontrib><description>Purpose of Review Despite ongoing research into alternative postsurgical pain treatments, opioids remain widely used analgesics regardless of associated adverse effects, including dependence and overdose, as demonstrated throughout the current opioid crisis. This is likely related to a failure in proving the efficacy of alternative analgesics in clinical trials, despite strong evidence supporting the potential for effective analgesia through in vitro studies. While NaV1.7 and NaV1.8 channels have shown to be key components of pain perception, studies regarding pharmacological agents utilizing these channels as targets have largely failed to demonstrate the efficacy of these proposed analgesics when compared to current multimodal pain treatment regimens. Recent Findings However, the novel NaV1.8 channel inhibitor, VX-548 has surpassed previously studied NaV1.8 inhibitors in clinical trials and continues to hold promise of a novel efficacious analgesic to potentially be utilized in multimodal pain treatment on postsurgical patients. Additionally, NaV1.8 is encoded by the SCN10A, which has been shown to be minimally expressed in the brain, suggesting a lower likelihood of adverse effects in the CNS, including dependence and abuse. Summary Novel pharmacologic analgesics that are efficacious without the significant side effects associated with opioids have lacked meaningful development. However, recent clinical trials have shown promising results in the safety and efficacy of the pharmacological agent VX-548. Still, more clinical trials directly comparing the efficacy of VX-548 to standard of care post-surgical drugs, including opioids like morphine and hydromorphone are needed to demonstrate the long-term viability of the agent replacing current opioids with an unfavorable side effect profile.</description><identifier>ISSN: 1531-3433</identifier><identifier>ISSN: 1534-3081</identifier><identifier>EISSN: 1534-3081</identifier><identifier>DOI: 10.1007/s11916-024-01295-7</identifier><identifier>PMID: 38963514</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Acute Pain - drug therapy ; Analgesics ; Analgesics - therapeutic use ; Chronic Pain Medicine (O Viswanath ; Clinical trials ; Drug overdose ; Humans ; Internal Medicine ; Medicine ; Medicine &amp; Public Health ; Narcotics ; NAV1.8 Voltage-Gated Sodium Channel ; Pain ; Pain Management - methods ; Pain Medicine ; Pain, Postoperative - drug therapy ; Section Editor ; Sodium Channel Blockers - pharmacology ; Sodium Channel Blockers - therapeutic use ; Topical Collection on Chronic Pain Medicine ; Voltage-Gated Sodium Channel Blockers - pharmacology ; Voltage-Gated Sodium Channel Blockers - therapeutic use</subject><ispartof>Current pain and headache reports, 2024-11, Vol.28 (11), p.1135-1143</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-3cb7832664a45aea833a71337993bd6d185375bde0a99a9ab6b62238dfbfa0c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11916-024-01295-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11916-024-01295-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38963514$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaye, Alan D.</creatorcontrib><creatorcontrib>Everett, Erin S.</creatorcontrib><creatorcontrib>Lehuquet, Arianna M.</creatorcontrib><creatorcontrib>Mason, Joseph W.</creatorcontrib><creatorcontrib>Maitski, Rebecca</creatorcontrib><creatorcontrib>Plessala, Michael J.</creatorcontrib><creatorcontrib>Barrie, Sonnah</creatorcontrib><creatorcontrib>Baptiste, Carlo Jean</creatorcontrib><creatorcontrib>Mychaskiw, George</creatorcontrib><creatorcontrib>Ahmadzadeh, Shahab</creatorcontrib><creatorcontrib>Shekoohi, Sahar</creatorcontrib><creatorcontrib>Varrassi, Giustino</creatorcontrib><title>Frontiers in Acute Pain Management: Emerging Concepts in Pain Pathways and the Role of VX-548 as a Novel NaV1.8 Inhibitor: A Narrative Review</title><title>Current pain and headache reports</title><addtitle>Curr Pain Headache Rep</addtitle><addtitle>Curr Pain Headache Rep</addtitle><description>Purpose of Review Despite ongoing research into alternative postsurgical pain treatments, opioids remain widely used analgesics regardless of associated adverse effects, including dependence and overdose, as demonstrated throughout the current opioid crisis. This is likely related to a failure in proving the efficacy of alternative analgesics in clinical trials, despite strong evidence supporting the potential for effective analgesia through in vitro studies. While NaV1.7 and NaV1.8 channels have shown to be key components of pain perception, studies regarding pharmacological agents utilizing these channels as targets have largely failed to demonstrate the efficacy of these proposed analgesics when compared to current multimodal pain treatment regimens. Recent Findings However, the novel NaV1.8 channel inhibitor, VX-548 has surpassed previously studied NaV1.8 inhibitors in clinical trials and continues to hold promise of a novel efficacious analgesic to potentially be utilized in multimodal pain treatment on postsurgical patients. Additionally, NaV1.8 is encoded by the SCN10A, which has been shown to be minimally expressed in the brain, suggesting a lower likelihood of adverse effects in the CNS, including dependence and abuse. Summary Novel pharmacologic analgesics that are efficacious without the significant side effects associated with opioids have lacked meaningful development. However, recent clinical trials have shown promising results in the safety and efficacy of the pharmacological agent VX-548. Still, more clinical trials directly comparing the efficacy of VX-548 to standard of care post-surgical drugs, including opioids like morphine and hydromorphone are needed to demonstrate the long-term viability of the agent replacing current opioids with an unfavorable side effect profile.</description><subject>Acute Pain - drug therapy</subject><subject>Analgesics</subject><subject>Analgesics - therapeutic use</subject><subject>Chronic Pain Medicine (O Viswanath</subject><subject>Clinical trials</subject><subject>Drug overdose</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Narcotics</subject><subject>NAV1.8 Voltage-Gated Sodium Channel</subject><subject>Pain</subject><subject>Pain Management - methods</subject><subject>Pain Medicine</subject><subject>Pain, Postoperative - drug therapy</subject><subject>Section Editor</subject><subject>Sodium Channel Blockers - pharmacology</subject><subject>Sodium Channel Blockers - therapeutic use</subject><subject>Topical Collection on Chronic Pain Medicine</subject><subject>Voltage-Gated Sodium Channel Blockers - pharmacology</subject><subject>Voltage-Gated Sodium Channel Blockers - therapeutic use</subject><issn>1531-3433</issn><issn>1534-3081</issn><issn>1534-3081</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQxi0EomXhBTggS1x6SfG_xE5vq1ULlUqpUFVxsybJZDdVYi-2s1UfgnfG7BaQOHCa0czv-2akj5C3nJ1yxvSHyHnNq4IJVTAu6rLQz8gxL6UqJDP8-b7nhVRSHpFXMd4zJpgx_CU5kqauZMnVMflxEbxLA4ZIB0eX7ZyQ3kBuP4ODNU7o0hk9nzCsB7emK-9a3KY9u6duIG0e4DFScB1NG6Rf_YjU9_TuW1EqQyFv6LXf4Uiv4Y6fGnrpNkMzJB_O6DLPQoA07LIOdwM-vCYvehgjvnmqC3J7cX67-lRcffl4uVpeFa0oq1TIttFGiqpSoEpAMFKC5lLqupZNV3XclFKXTYcM6hpqaKqmEkKarm96YK1ckJOD7Tb47zPGZKchtjiO4NDP0UqmS82UETyj7_9B7_0cXH7OSs6V0Erk6wsiDlQbfIwBe7sNwwTh0XJmf2VlD1nZnJXdZ2V1Fr17sp6bCbs_kt_hZEAegJhXbo3h7-3_2P4EnwWcvg</recordid><startdate>20241101</startdate><enddate>20241101</enddate><creator>Kaye, Alan D.</creator><creator>Everett, Erin S.</creator><creator>Lehuquet, Arianna M.</creator><creator>Mason, Joseph W.</creator><creator>Maitski, Rebecca</creator><creator>Plessala, Michael J.</creator><creator>Barrie, Sonnah</creator><creator>Baptiste, Carlo Jean</creator><creator>Mychaskiw, George</creator><creator>Ahmadzadeh, Shahab</creator><creator>Shekoohi, Sahar</creator><creator>Varrassi, Giustino</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20241101</creationdate><title>Frontiers in Acute Pain Management: Emerging Concepts in Pain Pathways and the Role of VX-548 as a Novel NaV1.8 Inhibitor: A Narrative Review</title><author>Kaye, Alan D. ; Everett, Erin S. ; Lehuquet, Arianna M. ; Mason, Joseph W. ; Maitski, Rebecca ; Plessala, Michael J. ; Barrie, Sonnah ; Baptiste, Carlo Jean ; Mychaskiw, George ; Ahmadzadeh, Shahab ; Shekoohi, Sahar ; Varrassi, Giustino</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-3cb7832664a45aea833a71337993bd6d185375bde0a99a9ab6b62238dfbfa0c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acute Pain - drug therapy</topic><topic>Analgesics</topic><topic>Analgesics - therapeutic use</topic><topic>Chronic Pain Medicine (O Viswanath</topic><topic>Clinical trials</topic><topic>Drug overdose</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Narcotics</topic><topic>NAV1.8 Voltage-Gated Sodium Channel</topic><topic>Pain</topic><topic>Pain Management - methods</topic><topic>Pain Medicine</topic><topic>Pain, Postoperative - drug therapy</topic><topic>Section Editor</topic><topic>Sodium Channel Blockers - pharmacology</topic><topic>Sodium Channel Blockers - therapeutic use</topic><topic>Topical Collection on Chronic Pain Medicine</topic><topic>Voltage-Gated Sodium Channel Blockers - pharmacology</topic><topic>Voltage-Gated Sodium Channel Blockers - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaye, Alan D.</creatorcontrib><creatorcontrib>Everett, Erin S.</creatorcontrib><creatorcontrib>Lehuquet, Arianna M.</creatorcontrib><creatorcontrib>Mason, Joseph W.</creatorcontrib><creatorcontrib>Maitski, Rebecca</creatorcontrib><creatorcontrib>Plessala, Michael J.</creatorcontrib><creatorcontrib>Barrie, Sonnah</creatorcontrib><creatorcontrib>Baptiste, Carlo Jean</creatorcontrib><creatorcontrib>Mychaskiw, George</creatorcontrib><creatorcontrib>Ahmadzadeh, Shahab</creatorcontrib><creatorcontrib>Shekoohi, Sahar</creatorcontrib><creatorcontrib>Varrassi, Giustino</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Current pain and headache reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaye, Alan D.</au><au>Everett, Erin S.</au><au>Lehuquet, Arianna M.</au><au>Mason, Joseph W.</au><au>Maitski, Rebecca</au><au>Plessala, Michael J.</au><au>Barrie, Sonnah</au><au>Baptiste, Carlo Jean</au><au>Mychaskiw, George</au><au>Ahmadzadeh, Shahab</au><au>Shekoohi, Sahar</au><au>Varrassi, Giustino</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Frontiers in Acute Pain Management: Emerging Concepts in Pain Pathways and the Role of VX-548 as a Novel NaV1.8 Inhibitor: A Narrative Review</atitle><jtitle>Current pain and headache reports</jtitle><stitle>Curr Pain Headache Rep</stitle><addtitle>Curr Pain Headache Rep</addtitle><date>2024-11-01</date><risdate>2024</risdate><volume>28</volume><issue>11</issue><spage>1135</spage><epage>1143</epage><pages>1135-1143</pages><issn>1531-3433</issn><issn>1534-3081</issn><eissn>1534-3081</eissn><abstract>Purpose of Review Despite ongoing research into alternative postsurgical pain treatments, opioids remain widely used analgesics regardless of associated adverse effects, including dependence and overdose, as demonstrated throughout the current opioid crisis. This is likely related to a failure in proving the efficacy of alternative analgesics in clinical trials, despite strong evidence supporting the potential for effective analgesia through in vitro studies. While NaV1.7 and NaV1.8 channels have shown to be key components of pain perception, studies regarding pharmacological agents utilizing these channels as targets have largely failed to demonstrate the efficacy of these proposed analgesics when compared to current multimodal pain treatment regimens. Recent Findings However, the novel NaV1.8 channel inhibitor, VX-548 has surpassed previously studied NaV1.8 inhibitors in clinical trials and continues to hold promise of a novel efficacious analgesic to potentially be utilized in multimodal pain treatment on postsurgical patients. Additionally, NaV1.8 is encoded by the SCN10A, which has been shown to be minimally expressed in the brain, suggesting a lower likelihood of adverse effects in the CNS, including dependence and abuse. Summary Novel pharmacologic analgesics that are efficacious without the significant side effects associated with opioids have lacked meaningful development. However, recent clinical trials have shown promising results in the safety and efficacy of the pharmacological agent VX-548. Still, more clinical trials directly comparing the efficacy of VX-548 to standard of care post-surgical drugs, including opioids like morphine and hydromorphone are needed to demonstrate the long-term viability of the agent replacing current opioids with an unfavorable side effect profile.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>38963514</pmid><doi>10.1007/s11916-024-01295-7</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1531-3433
ispartof Current pain and headache reports, 2024-11, Vol.28 (11), p.1135-1143
issn 1531-3433
1534-3081
1534-3081
language eng
recordid cdi_proquest_miscellaneous_3075704821
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Acute Pain - drug therapy
Analgesics
Analgesics - therapeutic use
Chronic Pain Medicine (O Viswanath
Clinical trials
Drug overdose
Humans
Internal Medicine
Medicine
Medicine & Public Health
Narcotics
NAV1.8 Voltage-Gated Sodium Channel
Pain
Pain Management - methods
Pain Medicine
Pain, Postoperative - drug therapy
Section Editor
Sodium Channel Blockers - pharmacology
Sodium Channel Blockers - therapeutic use
Topical Collection on Chronic Pain Medicine
Voltage-Gated Sodium Channel Blockers - pharmacology
Voltage-Gated Sodium Channel Blockers - therapeutic use
title Frontiers in Acute Pain Management: Emerging Concepts in Pain Pathways and the Role of VX-548 as a Novel NaV1.8 Inhibitor: A Narrative Review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T15%3A58%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Frontiers%20in%20Acute%20Pain%20Management:%20Emerging%20Concepts%20in%20Pain%20Pathways%20and%20the%20Role%20of%20VX-548%20as%20a%20Novel%20NaV1.8%20Inhibitor:%20A%20Narrative%20Review&rft.jtitle=Current%20pain%20and%20headache%20reports&rft.au=Kaye,%20Alan%20D.&rft.date=2024-11-01&rft.volume=28&rft.issue=11&rft.spage=1135&rft.epage=1143&rft.pages=1135-1143&rft.issn=1531-3433&rft.eissn=1534-3081&rft_id=info:doi/10.1007/s11916-024-01295-7&rft_dat=%3Cproquest_cross%3E3075704821%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3114274283&rft_id=info:pmid/38963514&rfr_iscdi=true